Muscle mass adjustment method affects association of sarcopenia and sarcopenic obesity with metabolic syndrome

Yılmaz, Özlem; Bahat, Gülistan

doi:10.1111/ggi.13609

Cited by 6 publications

(5 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Instead, the relation is curvilinear [ 28 ]. Moreover, it has been noticed that SMI based on height2 reflects lower muscle mass in people with a lower weight [ 29 ]. In addition, another SMI has been proposed, which considers other variables for adjustment such as weight or BMI [ 25 ].…”

Section: Discussionmentioning

confidence: 99%

Impact of Different Operational Definitions of Sarcopenia on Prevalence in a Population-Based Sample: The Salus in Apulia Study

Lampignano

Bortone

Castellana

et al. 2021

IJERPH

View full text Add to dashboard Cite

Background: In 2010, the European Working Group on Sarcopenia in Older People (EWGSOP1) issued its first operational definition to diagnose sarcopenia. This was updated in 2019 with a revised sequence of muscle mass and muscle strength (EWGSOP2). The aim of the study was to investigate the impact of these different operational definitions on sarcopenia prevalence in a representative population-based sample. Methods: For each algorithm, the prevalence of sarcopenia-related categories was calculated and related to sociodemographic and lifestyle variables, anthropometric parameters, and laboratory biomarkers. The present analysis used data from the Salus in Apulia Study (Italy, 740 subjects, mean age 75.5 ± 5.9 years, 54% women). Results: The application of the EWGSOP1 adapted algorithm resulted in 85% [95% confidence intervals (CI): 82–88%] non-sarcopenic subjects, 10% (95% CI: 8–12%) pre-sarcopenic subjects, and 5% (95% CI: 3–7%) sarcopenic/severe sarcopenic subjects. The sarcopenia-related categories were inversely related to weight and body mass index (BMI), particularly in overweight/obese subjects, and these categories showed favorable metabolic biomarkers. The EWGSOP2 algorithm yielded 73% (95% CI: 69–76%) non-sarcopenic subjects, 24% (95% CI: 21–27%) probably sarcopenic subjects, and 4% (95% CI: 2–5%) sarcopenic subjects. Conclusions: The present study identified BMI as a potential confounder of the prevalence estimates of sarcopenia-related categories in population-based settings with different EWGSOP operational definitions.

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of Different Operational Definitions of Sarcopenia on Prevalence in a Population-Based Sample: The Salus in Apulia Study

Lampignano

Bortone

Castellana

et al. 2021

IJERPH

View full text Add to dashboard Cite

show abstract

“…Sarcopenia is associated with increased adverse outcomes including falls, functional decline, frailty, and mortality (Bjorkman et al, 2019;Yang et al, 2019). Sarcopenia also reduces the amount of metabolically active tissue; thus, it increases the risk for metabolic diseases, including cardiovascular disease, diabetes, hypertension and hyperlipidemia and other elderly diseases (Biolo et al, 2014;Wang et al, 2018;Yilmaz and Bahat, 2019). This will bring heavy economic burden to the family of the elderly, society and medical service system.…”

Section: Introductionmentioning

confidence: 99%

Circulating MicroRNAs in Plasma Decrease in Response to Sarcopenia in the Elderly

Zhang

et al. 2020

Front. Genet.

View full text Add to dashboard Cite

sarcopenia has been defined as the aging-related disease with the declined mass, strength, and function of skeletal muscle, which is a major cause of morbidity and mortality in elders. Current diagnostic criteria of sarcopenia have not been agreed internationally, and the clinical diagnostic biomarkers for sarcopenia have not been identified. Circulating miRNAs (miRNAs, miRs) have recently been characterized as novel biomarkers for sarcopenia. However, the change of circulating miRNAs in response to sarcopenia are still not fully understood. Here, we enrolled a total of 93 elderly patients clinically diagnosed with sarcopenia and matching 93 non-sarcopenia elderly in this study. Specifically, levels of candidate circulating miRNAs which were involved in angiogenesis, inflammation and enriched in muscle and/or cardiac tissues were detected in these two groups. In small-sample screening experiments, plasma miR-155, miR-208b, miR-222, miR-210, miR-328, and miR-499 levels were significantly downregulated in sarcopenia compared to those who non-sarcopenia. In contrast, miR-1, mir-133a, miR-133b, miR-21, miR-146a, miR-126, miR-221, and miR-20a were not changed significantly. Subsequently, we expanded the sample size to further detection and verification, and found that plasma miR-155, miR-208b, miR-222, miR-210, miR-328, and miR-499 levels in the sarcopenia group were significantly reduced compared to the non-sarcoma group, which is consistent with the results of the small-sample screening experiment. In addition, we showed that ASM/Height2, handgrip strength, knee extension and 4-meter velocity in sarcopenia group were significantly lower than those in non-sarcopenia group. Here we correlated the decrease of miR-208b, miR-499, miR-155, miR-222, miR-328, and miR-210 in sarcopenia group and non-sarcopenia group with diagnostic indexes of sarcopenia (ASM/Height2, Handgrip strength and 4meter velocity) after adjusting sex. The results showed that miR-208b and miR-155 changes were significantly correlated with handgrip strength in woman, miR-208b, miR-499, and miR-222 changes were significantly correlated with ASM/Height2 in man, while other miRNAs changes did not show a strong correlation with these diagnostic indexes. In conclusion, plasma miR-208b, miR-499, miR-155, miR-222, miR-328, and miR-210

show abstract

“…Most previous studies investigating the association between MetS and SMM by dual DEXA [ 10 , 11 , 12 ] or BIA [ 13 , 14 ] revealed that an increased SMM reduces the risk of MetS, thus highlighting the positive effects of skeletal muscle on insulin control. Skeletal muscle is a major site for excess fat storage.…”

Section: Discussionmentioning

confidence: 99%

“…For example, a study on the relationship between sarcopenic obesity and MetS showed different results depending on the adjustment method. When muscle mass was corrected with height, muscle mass, and MetS, a positive association was revealed, whereas when muscle mass was corrected with BMI, a negative association was revealed [ 10 ].…”

Section: Discussionmentioning

confidence: 99%

“…The authors hypothesized that some muscle types lower the risk of MetS, whereas others increase it and that the amount of IMCLs may influence this risk. Most previous studies have measured muscle and fat mass using dual X-ray absorptiometry (DEXA) [ 10 , 11 , 12 ] or bioelectrical impedance analysis (BIA) [ 13 , 14 ]. These methods can easily measure the amount of subcutaneous or visceral fat but not that of IMCL.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Abdominal Muscles and Metabolic Syndrome According to Patient Sex: A Retrospective Cross-Sectional Study

et al. 2021

View full text Add to dashboard Cite

Computed tomography (CT) is a reference method for measuring skeletal muscle mass, and the amount of fat in the skeletal muscle can be calculated based on CT attenuation. This study aimed to comprehensively investigate the effect of muscle quality and quantity on metabolic syndrome (MetS) according to sex. This retrospective cross-sectional study enrolled 8081 individuals aged ≥20 years who underwent self-referral abdominopelvic CT at our hospital. The total abdominal muscle area (TAMA), low-attenuation abdominal muscle area (LAMA), normal-attenuation abdominal muscle area (NAMA), and extramyocellular lipid area (EMCLA) were measured using cross-sectional CT data of the L3 lumbar vertebrae. The TAMA and NAMA showed negative correlations with risk factors for MetS and a positive correlation with high-density lipoprotein cholesterol, whereas the LAMA and EMCLA showed an inverse trend in both the sexes (p < 0.001). After adjusting for various factors, a higher LAMA index and the ratio of LAMA to TAMA were associated with a higher prevalence of MetS. High TAMA indices were associated with a lower prevalence of MetS. Furthermore, muscle quality and quantity were associated with the prevalence of MetS in both males and females. However, the LAMA showed a stronger association with MetS in males than in females.

show abstract

Muscle mass adjustment method affects association of sarcopenia and sarcopenic obesity with metabolic syndrome

Cited by 6 publications

References 8 publications

Impact of Different Operational Definitions of Sarcopenia on Prevalence in a Population-Based Sample: The Salus in Apulia Study

Impact of Different Operational Definitions of Sarcopenia on Prevalence in a Population-Based Sample: The Salus in Apulia Study

Circulating MicroRNAs in Plasma Decrease in Response to Sarcopenia in the Elderly

Abdominal Muscles and Metabolic Syndrome According to Patient Sex: A Retrospective Cross-Sectional Study

Contact Info

Product

Resources

About